New shot shows promise for tough psoriasis cases

NCT ID NCT07008547

Completed Disease control Sponsor: SPH-BIOCAD (HK) Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tested netakimab, a biologic drug given as a shot, against a placebo in 202 Chinese adults with moderate-to-severe plaque psoriasis. The main goal was to see if netakimab could improve skin symptoms by at least 75% (PASI75) or achieve clear/almost clear skin (sPGA0/1) at 12 weeks. The study is complete, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Netakimab (a biologic drug given as a shot under the skin)
What this could lead to: If it works, this could offer a new treatment option for Chinese adults with moderate-to-severe plaque psoriasis who have not responded well to other therapies.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. As with any biologic, there may be risks like infections or allergic reactions. The benefit may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS

Contacts and locations

Locations

Peking University People's Hospital

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.